» Articles » PMID: 28795861

Linc00673 (ERRLR01) is a Prognostic Indicator of Overall Survival in Breast Cancer

Overview
Journal Transcription
Specialty Molecular Biology
Date 2017 Aug 11
PMID 28795861
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

LncRNAs are novel noncoding RNAs involved in the epigenetic regulation of gene expression by recruiting ribonucleoprotein complexes to specific genomic loci to initiate histone methylation and/or other chromatin modifications. LncRNAs themselves function as tumor suppressors or oncogenes, depending on the gene regulatory networks they govern. We identified lnc00673 (ERRLR01) as a marker of overall survival (OS) in breast cancer patients. Specifically, ERRLR01 levels were elevated in triple-negative breast cancer (TNBC) as compared with Luminal-A, Luminal-B, and HER2 breast cancer subtypes. ERRLR01 levels were also inversely correlated with breast cancer survival across all breast cancer patients. Upon stratification, OS in ERα tumors correlated with negative overall survival, while in ERα tumors, ERRLR01 correlated with positive outcomes. This suggests ERRLR01 is modulated by hormone signaling in breast cancer. Gene-network analysis revealed ERRLR01 correlated with distinct pathways including "epithelial development" and "cellular differentiation." These data suggest ERRLR01 operates as an oncogene in TNBC, as well as a biomarker in breast cancer patients.

Citing Articles

Exploiting Long Non-Coding RNAs and Circular RNAs as Pharmacological Targets in Triple-Negative Breast Cancer Treatment.

Palcau A, Brandi R, Mehterov N, Botti C, Blandino G, Pulito C Cancers (Basel). 2023; 15(16).

PMID: 37627209 PMC: 10453179. DOI: 10.3390/cancers15164181.


Long Non Coding RNA in Triple Negative Breast Cancer: A Promising Biomarker in Tumorigenesis.

Nandagopal S, Misra S, Sankanagoudar S, Banerjee M, Sharma P, Pane S Asian Pac J Cancer Prev. 2023; 24(1):49-59.

PMID: 36708551 PMC: 10152875. DOI: 10.31557/APJCP.2023.24.1.49.


Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment.

Li Y, Kong X, Wang Z, Xuan L J Cell Mol Med. 2022; 26(5):1351-1362.

PMID: 35150062 PMC: 8899180. DOI: 10.1111/jcmm.17124.


The Prognostic Value of LncRNA SLNCR1 in Cancers: A Meta-Analysis.

Cong L, Sun H, Hao M, Sun Q, Zheng Y, Cong X J Oncol. 2021; 2021:3161714.

PMID: 34733328 PMC: 8560271. DOI: 10.1155/2021/3161714.


Advances in Pathophysiology of Triple-Negative Breast Cancer: The Potential of lncRNAs for Clinical Diagnosis, Treatment, and Prognostic Monitoring.

Zhou Y, Yue Y, Fan S, Jia Q, Ding X Mol Biotechnol. 2021; 63(12):1093-1102.

PMID: 34245439 DOI: 10.1007/s12033-021-00368-x.


References
1.
De Craene B, Berx G . Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013; 13(2):97-110. DOI: 10.1038/nrc3447. View

2.
de Wit E, Vos E, Holwerda S, Valdes-Quezada C, Verstegen M, Teunissen H . CTCF Binding Polarity Determines Chromatin Looping. Mol Cell. 2015; 60(4):676-84. DOI: 10.1016/j.molcel.2015.09.023. View

3.
Werner A . Natural antisense transcripts. RNA Biol. 2006; 2(2):53-62. DOI: 10.4161/rna.2.2.1852. View

4.
Yang J, Li J, Shao P, Zhou H, Chen Y, Qu L . starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res. 2010; 39(Database issue):D202-9. PMC: 3013664. DOI: 10.1093/nar/gkq1056. View

5.
Jendrzejewski J, He H, Radomska H, Li W, Tomsic J, Liyanarachchi S . The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci U S A. 2012; 109(22):8646-51. PMC: 3365219. DOI: 10.1073/pnas.1205654109. View